ValuEngine upgraded shares of Misonix (NASDAQ:MSON) from a hold rating to a buy rating in a research note published on Thursday morning.
Shares of Misonix stock traded up $0.72 during trading on Thursday, reaching $17.25. 10,300 shares of the stock traded hands, compared to its average volume of 10,357. Misonix has a 52-week low of $8.25 and a 52-week high of $21.43.
Misonix (NASDAQ:MSON) last released its quarterly earnings results on Thursday, November 8th. The medical equipment provider reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The firm had revenue of $9.36 million for the quarter. Misonix had a negative net margin of 23.24% and a negative return on equity of 14.05%.
Several institutional investors have recently made changes to their positions in MSON. BlackRock Inc. boosted its holdings in shares of Misonix by 39.0% in the 2nd quarter. BlackRock Inc. now owns 25,660 shares of the medical equipment provider’s stock worth $318,000 after purchasing an additional 7,203 shares during the period. Renaissance Technologies LLC boosted its stake in Misonix by 13.4% during the second quarter. Renaissance Technologies LLC now owns 209,300 shares of the medical equipment provider’s stock worth $2,595,000 after buying an additional 24,754 shares during the period. Ingalls & Snyder LLC purchased a new position in Misonix during the third quarter worth $1,130,000. Acadian Asset Management LLC boosted its stake in Misonix by 388.8% during the third quarter. Acadian Asset Management LLC now owns 8,212 shares of the medical equipment provider’s stock worth $152,000 after buying an additional 6,532 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Misonix by 1,487.5% during the third quarter. Wells Fargo & Company MN now owns 6,350 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 5,950 shares during the period. Hedge funds and other institutional investors own 15.94% of the company’s stock.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
See Also: Back-End Load
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.